



Universiteit
Leiden
The Netherlands

Clinical application of biomarkers in colon cancer : studies on apoptosis, proliferation and the immune system

Zeestraten, E.C.M.

Citation

Zeestraten, E. C. M. (2014, September 17). *Clinical application of biomarkers in colon cancer : studies on apoptosis, proliferation and the immune system*. Retrieved from <https://hdl.handle.net/1887/28735>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/28735>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/28735> holds various files of this Leiden University dissertation

Author: Zeestraten, Eliane

Title: Clinical application of biomarkers in colon cancer : studies on apoptosis, proliferation and the immune system

Issue Date: 2014-09-17

List of publications

DNA methylation of apoptosis genes in rectal cancer predicts patient survival an tumor recurrence. E. Zeestraten, A. Benard, I. Goossens-Beumers, H. Putter, C. van de Velde, D. Hoon, P. Kuppen. Accepted in Apoptosis

Clinical prognostic value of combined analysis of Aldh1, Survivin and EpCAM expression in colorectal cancer. I. Goossens-Beumer, E. Zeestraten, A. Benard, T. Christen, M. Reimers, R. Keijzer, C. Sier, GJ Liefers, H. Morreau, H. Putter, A. Vahrmeijer, C. van de Velde, P. Kuppen. Br. J. Cancer. 2014; 110 (12): 2935-44

Combined analysis of HLA Class I, HLA-E and HLA-G predicts prognosis in colon cancer patients. E. Zeestraten, M. Reimers, S. Saadatmand, J. Dekker, G. Liefers, C. van de Velde, P. Kuppen. Br. J. Cancer. 2014; 10(2): 459-68

The homeobox gene MEIS1 is methylated in BRAFV600E mutated colon tumors. A. Diha, A. Boot, E. van Roon, M.Schrumpf, A. Farina-Sarasqueta, M. Fiocco, E. Zeestraten, P. Kuppen, H. Morreau, T. van Wezel, J. Boer. Plos One. 2013; 8 (11)

Biomarkers and precision medicine in CRC. M. Reimers, E. Zeestraten, P. Kuppen, G. Liefers, C. van de Velde. Gastroenterology Rep. 2013; 1(3): 166-83

231

The prognostic value of the apoptosis pathway in colorectal cancer; a review of the literature on biomarkers identified by immunohistochemistry. E. Zeestraten, A. Benard , M. Reimers, P. Schouten, G. Liefers, C. van de Velde , P. Kuppen. Biomarkers in Cancer. 2013; 5: 13-29

Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. M. Maak, I. Simon, U. Nitsche, P. Roepman, M. Snel, A. Glas, T. Schuster, G. Keller, E. Zeestraten, I. Goossens, KP. Janssen, H. Friess, R. Rosenberg. Ann. Surg. 2013; 257 (6):1053-8

The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. A. Huijbers, R. Tollenaar, G.v Pelt, E. Zeestraten, S. Dutton, C. McConkey, E. Domingo, V. Smit, R. Midgley, B. Warren, E. Johnstone, D. Kerr, W. Mesker. Ann. Oncol. 2013; 24(1): 179-85

Addition of interferon- α to the p53-SLP[®] vaccine results in increased production of interferon- γ in vaccinated colorectal cancer patients: a phase I/II clinical trial. E. Zeestraten, F. Speetjens, M. Welters, S. Saadatmand, L. Stynenbosch, R. Jongen, E. Kapiteijn, H. Gelderblom, H. Nijman, A. Valentijn, J. Oostendorp, L. Fathers, J. Drijfhout, C. van de Velde, P. Kuppen, S. van der Burg, C. Melief. Int. J. Cancer. 2012; 132(7): 1581-91

Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer. E. Zeestraten, M. Maak, M. Shibayama, T. Schuster, U. Nitsche, T. Matsushima, S. Nakayama, K. Gohda, H. Friess, C. van de Velde, H. Ishihara, R. Rosenberg, P. Kuppen, KP. Janssen. *Br. J. Cancer*. 2012; 106: 133-140

FoxP3- and CD8-positive Infiltrating Immune Cells Together Determine Clinical Outcome in Colorectal Cancer. E. Zeestraten, A. van Hoesel, F. Speetjens, A. Menon, H. Putter, C. van de Velde, P. Kuppen. *Cancer Microenviron*. 2012; 6(1): 31-9

Prediction in rectal cancer. E. Zeestraten, P. Kuppen, C. van de Velde, C. Marijnen. *Semin. Radiat. Oncol*. 2012; 22(2): 175-83

Transanal endoscopic microsurgery for T1 rectal cancer: size matters! P. Doornebosch, E. Zeestraten, E. de Graaf, P. Hermsen, I. Dawson, R. Tollenaar, H. Morreau. *Surg. Endosc*. 2012; 26(2): 551-7

PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. A. Fariña Sarasqueta, E. Zeestraten, T. van Wezel, G. van Lijnschoten, R. van Eijk, J. Dekker, P. Kuppen, I. Goossens-Beumer, V. Lemmens, C. van de Velde, H. Rutten, H. Morreau, A. van den Brule. *Cell. Oncol*. 2011; 34(6): 523-31

Colorectal cancer vaccines in clinical trials. F. Speetjens, E. Zeestraten, P. Kuppen, C. Melief, S. van der Burg, *Expert. Rev. Vaccines*. 2011; 10(6): 899-921

PIK3CA mutations predict local recurrences in rectal cancer patients. Y. He, L. Van't Veer, I. Mikolajewska-Hanclich, M. van Velthuysen, E. Zeestraten, I. Nagtegaal, C. van de Velde, C. Marijnen. *Clin. Cancer Res*. 2009; 15(22): 6956-62

Clinical impact of HLA class I expression in rectal cancer. F. Speetjens, E. de Bruin, H. Morreau, E. Zeestraten, H. Putter, J. van Krieken, M. van Buren, M. van Velzen, N. Dekker-Ensink, C. van de Velde, P. Kuppen. *Cancer Immunol. Immunother*. 2008; 57(5): 601-9

Pediatric outcome in Rhesus hemolytic disease treated with and without intrauterine transfusion. I. De Boer, E. Zeestraten, E. Lopriore, I. van Kamp, H. Kanhai, F. Walther. *Am. J. Obstet. Gynecol*. 2008; 198(1):54e1-4

Combined markers of tumor cell proliferation and apoptosis are clinically prognostic in stage II colon cancer patients. E. Zeestraten, G. van Pelt, I. Goossens-Beumer, U. Nitsche, M. Maak, R. Rosenberg, K.P. Janssen, G. Liefers, C. van de Velde, P. Kuppen. Submitted for publication

Nuclear expression of histone deacetylases and their histone modifications predicts clinical outcome in colorectal cancer. A. Benard, I. Goossens-Beumer, A. van Hoesel, H. Horati, W. de Graaf, H. Putter, E. Zeestraten, GJ Liefers, C. van de Velde, P. Kuppen. Submitted for publication

Polycomb proteins EZH2, BMI1 and SUZ12 and histone modification H3K27me3 predict clinical outcome in colorectal cancer. A. Benard, I. Goossens-Beumer, A. van Hoesel, H. Horati, H. Putter, E. Zeestraten, C. van de Velde, P. Kuppen. Submitted for publication

Histone methylation at H3K4, H3K9 and H4K20 predicts patient survival and tumor recurrence in early stage colon cancer. A. Benard, I. Goossens-Beumer, A. van Hoesel, W. de Graaf, H. Horati, H. Putter, E. Zeestraten, C. van de Velde, P. Kuppen. Submitted for publication

Age-dependent clinical prognostic value of histone modifications in colorectal cancer. I. Goossens-Beumer, A. Benard, E. Zeestraten, H. Putter, S. Bohringer, GJ. Liefers, C. van de Velde, P. Kuppen. Submitted for publication

Acknowledgements

To start off I would like to state that I'm not a molecular biologist or a scientist for that matter, I am a clinician in training of becoming a surgeon and hopefully a scientist. The studies, which resulted in this thesis, could therefore not have been made possible without the help of many others, and most of all, very wise people. I would like to thank all of you who have been of such great help in this process. My supervisors for their patience, wisdom and guidance and my colleagues at the laboratory both in Leiden as well as in the JWCI for their inexhaustible support. Furthermore, everyone from the Surgical and Clinical Oncology Department and the Department of Pathology of the LUMC in Leiden and our colleagues at the Rechts an der Isar Klinikum and the TU in Munich who contributed one way or another to the completion of this thesis, thank you all very much.

Throughout this whole process I was lucky to receive the support of many people from both inside of the hospital (at the LUMC in Leiden, the GHZ in Gouda, at the Erasmus MC in Rotterdam and at the IJsselland Ziekenhuis in Capelle a/d IJssel) as well as outside the hospital (Rapenburg 120, Jaar 2001, my year club and many other friends) that enabled me to actually finish what I started. Thank you all very much.

234

Finally, these acknowledgements would not be complete without a special thank you to Lot Ultee, Emmeline van Heukelem and Agnès Zeestraten. Whether it was as my best friend, my paranymp or my sister, any way you supported me throughout this process is much appreciated.

Dear mom and dad, I am so very grateful to you. Thank you for a great childhood, all of the opportunities you provided me with and your never ending support, love and understanding. Dear Godard, I am so happy I met you, thank you for support in something that was so important to me these past three years.

Curriculum vitae

Eliane Cornelia Maria Zeestraten was born on May 17th 1983 in Heerlen, the Netherlands. After graduating cum laude from the Gymnasium of the Bernardinus College in Heerlen in 2001, she started studying medicine that same year at the University of Leiden, the Netherlands. During her medical training she performed two research projects. The first one entitled; 'Pediatric outcome in Rhesus hemolytic disease treated with and without intrauterine transfusion' at the department of Neonatology in the LUMC in Leiden under the supervision of Dr. I. de Boer and Prof. Dr. F.J. Walther. The second one; 'Clinical impact of HLA class I expression in rectal cancer', at the department of Surgery in the LUMC under the supervision of Dr. P.J.K. Kuppen and Prof. Dr. C.J.H van de Velde. After graduating in 2007 she commenced with her medical rotations, obtaining her medical degree on September 27th 2009. Because of her great interest in academic research as well as the surgical profession, she choose to work on a PhD project at the Surgical Oncology research group of the department of Surgery in the LUMC. This PhD project that resulted in the current thesis was performed under supervision of Prof. Dr. C.J.H van de Velde and the co-supervisors Dr. P.J.K Kuppen and Dr. G.J. Liefers. During this four year period she spend 9 months at the Department of Molecular Oncology of the John Wayne Cancer Institute at Saint John's Health Center in Santa Monica, California, USA under the supervision of Dr. D.S.B. Hoon, performing additional studies on the clinical relevance of methylation profiles of apoptotic genes in rectal cancer. The results will be published in Apoptosis in the near future.

235

After the four years she spent working on her PhD project she began her clinical training as a surgical resident (not in training) at the Groene Hart Hospital in Gouda, the Netherlands (head: Dr. R.F. Schmitz). In July 2012 she started her general surgical training at the Erasmus MC in Rotterdam, the Netherlands. (supervisor; Dr. B.P.L Wijnhoven) Currently, she is working as a surgical resident in training at the IJsselland hospital in Capelle a/d IJssel, the Netherlands. (supervisor; Dr. I. Dawson)

